Clinical trials: Sepsis-associated Acute Kidney Injury, open to volunteers
Acute Kidney Injury
Investigations Into Sepsis-associated Acute Kidney Injury
In this study the investigators would like to study systemic and regional disturbances in patients with sepsis-associated acute kidney injury and in healthy controls undergoing laparoscopic abdominal surgery.
- Trial name
- NCT05694624
- Testing
- Para Aminohippurate
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- University Hospital of North Norway
Acute Kidney Injury, Sepsis
MULTIMODAL APPROACH IN THE DIAGNOSIS OF SEPTIC AKI
In recent studies, it has been reported that the renal resistance index is effective in detecting sepsis-related acute renal failure (SA-AKI) in the early period.
- Conditions
- Acute Kidney Injury, Sepsis, Critical Illness, Renal Resistive Index
- Trial name
- SEPTIC AKI (NCT07472452)
- Testing
- Renal Resistive Index (RRI) Doppler Ultrasound, Urinary TIMP-2 and IGFBP-7 biomarkers
- Volunteers
- 130 people
- Sponsor
- Ankara Etlik City Hospital
Sepsis, Acute Kidney Injury Due to Sepsis
Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury
Sepsis is a major cause of morbidity and mortality in intensive care units. Sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) are common complications associated with adverse clinical…
- Conditions
- Sepsis, Acute Kidney Injury Due to Sepsis, Gastrointestinal Microbiome, Sepsis-Associated Liver Injury
- Trial name
- MESH (NCT07735182)
- Where
- 6 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Kidney Injury, Sepsis
Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury
The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the…
- Trial name
- IRON-IC (NCT07236463)
- Testing
- Continuous veino-veinous dialysis with iron-chelator supplemented dialysate
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Sepsis, Surgery
Inflammatory Mediators of Acute Kidney Injury in Intensive Care
Acute kidney injury (AKI) affects more than 50% of patients admitted to the intensive care unit. The most common underlying cause is sepsis. Severe AKI in combination with sepsis is associated with high mortality.
- Conditions
- Sepsis, Surgery, Acute Kidney Injury
- Trial name
- PronMed (NCT03720860)
- Where
- Sweden
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Sepsis-associated AKI
Oxiris in Septic AKI
Sepsis is a leading cause of acute kidney injury (AKI) in critically ill patients, with sepsis-associated AKI accounting for approximately 50% of all AKI cases in the intensive care unit.
- Trial name
- NCT07641660
- Testing
- Oxiris, Standard CRRT
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Samsung Medical Center
Liver Cirrhosis, Acute Kidney Injury
Comparison of Safety and Efficacy of Tailored Versus Fixed Dose Albumin for the Management of Patients With Cirrhosis and Sepsis Associated Acute Kidney Injury
Acute kidney injury accompanies about 20% of hospitalized patients with cirrhosis and in about 40% of those admitted to ICU.A critically ill patient with cirrhosis refers to an individual who has advanced liver disease…
- Trial name
- NCT06809088
- Testing
- Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Sepsis, Acute Kidney Injury
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
This multicenter, randomized, open-label, active-controlled, parallel-group trial will evaluate the efficacy and safety of nafamostat mesylate anticoagulation compared with regional citrate anticoagulation in adult patients with…
- Conditions
- Sepsis, Acute Kidney Injury, Continuous Renal Replacement Therapy (CRRT)
- Trial name
- NICE-AKI (NCT07518303)
- Testing
- Citrate anticoagulation, Nafamostat Mesylate
- Volunteers
- 1,162 people
- Sponsor
- Jianfeng Xie
Sepsis, Acute Kidney Injury
Immune Evaluation for Postoperative Sepsis-AKI
This prospective, multicenter, observational cohort study plans to enroll over 800 patients with postoperative sepsis from the ICUs of two tertiary hospitals in Beijing.
- Trial name
- NCT07811544
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Beijing Chao Yang Hospital
Sepsis
Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI
The goal of this clinical trial is to compare the safety and efficacy of nafamostat mesylate (NM) and unfractionated heparin (UFH) in the process of renal replacement therapy (RRT) for patients suffering from sepsis associated…
- Trial name
- NCT06375616
- Testing
- Nafamostat Mesylate, Unfractionated Heparin
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shen Lei
Septic Shock, Acute Kidney Injury
Early Endotoxin Burden Reduction With oXiris in Septic Shock Patients Requiring CRRT
The goal of this clinical trial is to learn whether continuous renal replacement therapy (CRRT) using the oXiris filter can lower the amount of endotoxin in the blood of adults with septic shock who need CRRT.
- Trial name
- NCT07807410
- Testing
- oXiris Hemofilter
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sepsis, Acute Kidney Injury
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within…
- Trial name
- SERENIA (NCT07215702)
- Testing
- AZD4144
- Where
- 74 sites in United States, Argentina and 12 more
- Volunteers
- 124 people
- Sponsor
- AstraZeneca